Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsLeonard S. Schleifer, M.D., Ph.D. is recorded as Chairman at Regeneron Pharmaceuticals, Inc. (REGN) since April 17, 2023. Regeneron Pharmaceuticals, Inc. reported in an 8-K filed April 17, 2023 that Leonard S. Schleifer, M.D., Ph.D. was appointed Co-Chair of the Board. Leonard S. Schleifer, M.D., Ph.D. has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on June 12, 2026. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes George D. Yancopoulos, M.D., Ph.D. (Chairman), Joseph J. LaRosa (General Counsel), Christine A. Poon (Board Member) and 7 others.
“Effective upon the expiration of Dr. Vagelos’s term, the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board (in addition to Dr. Schleifer’s and Dr. Yancopoulos’s continued roles as President and Chief Executive Officer and President and Chief Scientific Officer, respectively) and to designate Christine A. Poon as the Lead Independent Director of the Board.”
“If any shareholder has a question relating to any of the proposals, please submit it using the virtual meeting website and identify yourself. As a reminder, there will be ample opportunity for general questions about the company later in the proceedings.”
“We were pleased with Regeneron's performance to start 2026, highlighted by strong commercial execution across our key growth products, continued pipeline progress, a disciplined approach to capital allocation, and our agreement with the U.S. government to lower drug prices for American patients while preserving…”
2023-04-17–present
Biotechnology · Healthcare
Chairman
2023-04-17–present
